John Canepa
Chief Executive Officer
Mr. Canepa joined U.S. Genomics as Chief Financial Officer in October 2003. During his tenure at U.S. Genomics, Mr. Canepa guided the Company through the development and launch of the Trilogy® 2020 platform and assays, a round of venture capital financing and through two phases of a multi-million-dollar biodefense contract with the U.S. Department of Homeland Security. The Board of Directors appointed him to the position of Chief Executive Officer in November 2005. Prior to joining U.S. Genomics, Mr. Canepa served as Vice President, Finance & Administration, and Chief Financial Officer of Winphoria Networks, Inc., a venture capital-backed wireless telecommunications company. Under Mr. Canepa's direction, Winphoria raised more than $60 million of equity and debt financing prior to its acquisition by Motorola in May 2003. Mr. Canepa was instrumental in structuring business development arrangements and in negotiating the sale of the company to Motorola. Previously he was a senior partner in the Boston office of Arthur Andersen, where he led the firm's worldwide life sciences practice.  Mr. Canepa holds a Masters in Finance from Michigan State University and a B.A. from Denison University.  

John Harris
Vice President, Engineering and Manufacturing
Mr. Harris came to U. S. Genomics from Applied Biosystems, where he was a senior program manager.  In this role, he was responsible for R&D project management at the company's Framingham facility. Mr. Harris worked at PerSeptive Biosystems prior to their acquisition by Applied Biosystems. While at PerSeptive/ABI, Mr. Harris managed many development programs resulting in the introduction of new chromatography instruments, and upgrades to existing product lines. Mr. Harris brings over 20 years of experience with instrument development in the fields of fermentation, downstream processing, mass spectrometry and microfluidics. Mr. Harris holds a B.S. in Electrical Engineering from Imperial College, London University, England.

David Hoey
Vice President, Business Development
Mr. Hoey brings over 15 years of business development and financing expertise to U.S. Genomics. Most recently, Mr. Hoey was Vice President, Marketing and Business Development of InfoLibria, Inc., a developer of Internet infrastructure solutions. Mr. Hoey also served as Vice President of Business Development at Molten Metal Technology, Inc., where he developed and maintained corporate alliances and joint ventures both in the U.S. and abroad. Mr. Hoey has completed over $400 million in corporate collaborations and financings, and he served as consultant to, and Board Member of, Bligh Ventures Limited, a publicly traded Australian venture capital firm with strategic investments in biotechnology, software development, and telecommunications.

Rudolf Gilmanshin, Ph.D.
Vice President, Advanced Platform Research
Dr. Gilmanshin joined U.S. Genomics in June of 1998 as the first employee of the company. He has made substantial contributions to the development of all technology platforms. Dr. Gilmanshin came to U.S. Genomics from Albert Einstein College of Medicine, New York, where he studied structural transformations of protein molecules. He brings over 27 years of research experience, including work at Los Alamos National Laboratory, various universities, and the Russian Academy of Sciences where he studied protein folding, molecular films, and dynamics of biomolecular systems. Dr. Gilmanshin attained his Ph.D. in Molecular Biophysics from the Institute of Protein Research at the Russian Academy of Sciences. He also holds an M.S. in Physics of Fast Processes from the Moscow Institute of Physics and Technology and has authored 36 papers and several patents.